The US Food and Drug Administration has reduced requirements for preclinical animal testing, leading to a surge of interest in organoids, tissue chips and in silico testing.

The entire biotechnology and pharmaceutical industry will be thrown into turmoil if judges can second-guess the scientific expertise of the US Food and Drug Administration.

Activating the PD-1 checkpoint might reset the immune system and reduce disease activity in patients with rheumatoid arthritis, according to a phase 2a trial.

Patients, physicians, and hospital administrators in the USA are often unaware of how legislation governs medical data—but agree that rights over such data should be expanded for patients and curtailed for health systems

We read with great interest the editorial on the importance of a global approach to dementia research1. We agree that a global approach to research into the mechanisms, prevalence, risk factors and prevention of dementia is needed. We would like to highlight an additional and crucial aspect of dementia research that was not mentioned in the editorial but also requires a global approach: care for people

Anti-poverty programs can alleviate the negative impact of low family income on brain structure and mental health in adolescents.

Artificial intelligence (AI) systems are increasingly being investigated in clinical trials. Trials that use AI must be held to the same ethical standards for risk assessment and disclosure as all human participant studies. All clinical AI systems, especially those under active investigation, have new risks, including human–machine interactions, interpretability and data limitations. The full magnitude

Evidence-based medicine (EBM) requires the retrieval and ranking of relevant evidence by epistemological strength, to identify the most appropriate evidence to inform guidelines and policies, with a preference for robust evidence from randomized clinical trials (RCTs), systematic reviews, and meta-analyses. The explosive growth of the scientific literature and the emergence of new sources of evidence

In a clinical trial, interrupting adjuvant endocrine therapy to attempt pregnancy did not increase the risk of breast cancer recurrence.

Nature Medicine explores the latest translational and clinical research news, with FDA approval of Seres’ orally administered pill SER-109 for the treatment of recurrent Clostridioides difficile infection.

Multilevel stakeholder engagement in policy decision-making and implementation-planning is needed to build trust and deliver evidence-based health interventions.

Researchers have developed a non-invasive brain–computer interface that reconstructs narratives from perceived or imagined speech.

Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.

From menarche to menopause, menstrual health is intrinsically linked to general health and must find regular attention in clinical practice.

Physician burnout has reached alarming levels, with 63% of US physicians reporting feeling emotional exhaustion or depersonalization1. The use of electronic health records and the burden of clinical documentation are seen as major factors contributing to this issue. Physicians, administrators and medical societies are searching for solutions to address this epidemic. One potential solution being considered

These interventions for women and girls improve population health and boost the economy.

A multiorgan model unravels the inter-organ aging network and predicts chronic diseases and mortality

A thromboprotective platelet signature, conserved across species, could provide new therapeutic targets for the treatment of venous blood clots in immobilized patients.

Nature Medicine explores the latest translational and clinical research news, with a phase 1/2 trial of a dual CAR T cell therapy that targets gp120.

The recent correspondence by Sjoberg et al.1 highlighted several commendable stewardship initiatives, developed for human medicine, that have been embraced by companion animal veterinarians and integrated into practice. Antibiotic use guidelines, including the PROTECT ME poster (see https://go.nature.com/3Hn7qcl), have been developed to encourage veterinarians to optimize their selection of the right

Real-world data reflect the diversity and lived experiences of individuals and so should be a central pillar of clinical research and care.

Randomization and placebo groups are giving way to biomarkers, real-world data from wearables, and multi-center and adaptive trials.

Uninterrupted embryo culture and time-lapse monitoring are increasingly offered to people undergoing IVF — but a randomized study fails to show any benefit over routine embryo-selection methods.

The PHYSIC trial reveals substantial variability in how people respond to four different classes of blood-pressure-lowering drugs — highlighting the need to personalize treatments.

A new study provides the strongest support yet for abnormal α-synuclein as a diagnostic biomarker that shows up even in the prodromal phase — with immediate implications for trial design and therapeutic development.